Navigation Links
Industry group release testing recommendations for oligonucleotide-based therapeutics
Date:7/8/2014

New Rochelle, NY, July 8, 2014Novel oligonucleotide-based drugs in development offer promising alternatives for treating a range of diseases. A group of industry and regulatory scientists developing these new nucleic acid-based therapies released consensus recommendations for evaluating the pharmacological safety of oligonucleotide therapeutics. The document is published in Nucleic Acid Therapeutics, a peer-reviewed journal from Mary Ann Liebert, Inc. publishers. The article is available on the Nucleic Acid Therapeutics website.

Cindy Berman and coauthors from Pfizer Pharmaceuticals, GlaxoSmithKline, Preclinsight, Merck Sharp & Dohme Corp., Tepper Nonclinical Consulting, and Isis Pharmaceuticals provide the consensus opinion of the Safety Pharmacology Subcommittee of the Oligonucleotide Safety Working Group in the article "Recommendations for Safety Pharmacology Evaluations of Oligonucleotide-Based Therapeutics." The recommendations emphasize in particular the importance of safety pharmacology studies to evaluate the potential effects of systemically administered oligonucleotide-based drugs on cardiovascular function.

"It is our hope that during this period of rapid advancement both regulators and researchers alike will recognize and benefit from these carefully considered safety testing recommendations," says Executive Editor Graham C. Parker, PhD, The Carman and Ann Adams Department of Pediatrics, Wayne State University School of Medicine, Children's Hospital of Michigan, Detroit, MI.


'/>"/>

Contact: Kathryn Ruehle
kruehle@liebertpub.com
914-740-2100
Mary Ann Liebert, Inc./Genetic Engineering News
Source:Eurekalert  

Page: 1

Related biology news :

1. Gray seals consume as much fish as the fishing industry catches
2. Saving forests? Take a leaf from insurance industrys book
3. Global Laboratory Automation Industry
4. How will the US biotechnology industry benefit from new patent laws?
5. NIST launches new website to educate industry about alternatives to mercury thermometers
6. Work starts on fossil fuel free cargo ship set to transform shipping industry
7. Pilot Results Move GHX Closer to Delivery of Healthcare Industrys First Implantable Device Supply Chain Solution
8. Food industrys high-quality co-streams used effectively as raw material for new products
9. Remarkable enzyme points the way to reducing nitric acid use in industry
10. Crank Software Selects TREW Marketing for Embedded Industry Outreach
11. Plastic packaging industry is moving towards completely bio-based products
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Industry group release testing recommendations for oligonucleotide-based therapeutics
(Date:1/12/2017)... research undertaken by Fit Small Business has revealed ... simply asked which office technology had they not used in ... Insights on what will be key features in ... industry leaders including Penelope Trunk , Martin Lindstrom ... Some of these findings included; ...
(Date:1/11/2017)... 2017 Intoxalock, a leading ignition interlock provider, ... its patent-pending calibration device. With this new technology, Intoxalock ... upload data logs and process repairs at service center ... "Fighting drunk driving through the application of cutting-edge technologies ... but also for the customer who can get back ...
(Date:1/6/2017)... 2017  Privately-held CalciMedica, Inc., announced that it ... of a novel calcium release-activated calcium (CRAC) channel ... Acute pancreatitis, sudden painful inflammation of ... can be very serious.  In severe cases it can ... hospital stays, time in the ICU and substantial ...
Breaking Biology News(10 mins):
(Date:1/21/2017)... ... 20, 2017 , ... Nipro Corporation (Osaka, Japan) and Transonic Systems Inc. (New ... receive exclusive marketing and sales rights for all non-OEM Transonic products in Japan. As ... Japan, the new Nipro - Transonic JV is a natural next step to advance ...
(Date:1/21/2017)... , Jan. 21, 2017   Boston Biomedical , ... designed to target cancer stemness pathways, today presented data ... napabucasin, at the 2017 American Society of Clinical Oncology ... . In a Phase Ib/II ... designed to inhibit cancer stemness pathways by targeting STAT3 ...
(Date:1/20/2017)... ... January 20, 2017 , ... ... announced today the next evolution in spinal fusion, the MISquito Percutaneous Pedicle ... to the competition, SpineFrontier is focused on technique driven product solutions that ...
(Date:1/19/2017)... Research and Markets ... announced the addition of the "Implantable Biomaterials Market ... report to their offering. Report Highlights: ... analysis on current and future market trends to identify the investment opportunities ... the base numbers Key market trends across the business ...
Breaking Biology Technology: